<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE315nnn/GSE315511/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Mus musculus</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315511</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Attenuation of oxygen-induced neovascularization and inflammation by neutralizing antibody to VEGFA and/or ANG-2</name><description>Neovascularization is a major cause of blindness in various retinal diseases, and inflammation aggravates the pathological and clinical conditions of these diseases. VEGFA or ANG-2 neutralizing antibodies have been used to block pathological neovascularization. In this work, the effects of intraocular administration of neutralizing antibodies against VEGFA, ANG-2, or bispecific to these two factors on pathological findings were examined in the oxygen-induced retinopathy (OIR) mouse model. At both postnatal day (P)17 and P19, anti-VEGFA and -ANG-2 administration suppressed neovascularization, and the bispecific antibody attenuated neovascularization more efficiently. However, oxygen-induced vaso-obliteration was not modified by these antibodies. Numbers of photoreceptor, amacrine, and bipolar cells were reduced in the OIR retina, and the antibodies reversed these changes. Microglia-specific gene expression increased in the OIR retina, and administration of the antibodies reduced the IBA1-positive area in the OIR retina, although these antibodies did not affect marker gene expression. Labeled VEGFA and ANG-2 were found to be co-localized with microglia, suggesting that VEGFA and ANG-2 affect microglia activation directly. Taken together, neutralizing antibody to VEGFA or ANG-2 attenuated oxygen-induced neovascularization and inflammation, and the bispecific antibody more efficiently suppressed some features than the single antibody to VEGFA or ANG-2.</description><dates><publication>2026/04/15</publication></dates><accession>GSE315511</accession><cross_references><GSM>GSM9429790</GSM><GSM>GSM9429794</GSM><GSM>GSM9429793</GSM><GSM>GSM9429792</GSM><GSM>GSM9429791</GSM><GSM>GSM9429798</GSM><GSM>GSM9429797</GSM><GSM>GSM9429796</GSM><GSM>GSM9429795</GSM><GSM>GSM9429813</GSM><GSM>GSM9429812</GSM><GSM>GSM9429811</GSM><GSM>GSM9429799</GSM><GSM>GSM9429810</GSM><GSM>GSM9429817</GSM><GSM>GSM9429816</GSM><GSM>GSM9429815</GSM><GSM>GSM9429814</GSM><GSM>GSM9429819</GSM><GSM>GSM9429818</GSM><GSM>GSM9429787</GSM><GSM>GSM9429820</GSM><GSM>GSM9429786</GSM><GSM>GSM9429785</GSM><GSM>GSM9429802</GSM><GSM>GSM9429824</GSM><GSM>GSM9429801</GSM><GSM>GSM9429823</GSM><GSM>GSM9429822</GSM><GSM>GSM9429789</GSM><GSM>GSM9429800</GSM><GSM>GSM9429788</GSM><GSM>GSM9429821</GSM><GSM>GSM9429806</GSM><GSM>GSM9429805</GSM><GSM>GSM9429804</GSM><GSM>GSM9429803</GSM><GSM>GSM9429809</GSM><GSM>GSM9429808</GSM><GSM>GSM9429807</GSM><GPL>24247</GPL><GSE>315511</GSE><taxon>Mus musculus</taxon><PMID>[41944819]</PMID></cross_references></HashMap>